Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-17-007984
Filing Date
2017-07-27
Accepted
2017-07-27 17:17:05
Documents
6
Period of Report
2017-07-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT f8k072717a1_immucellcorp.htm 8-K/A 22711
2 OPINION OF PIERCE ATWOOD LLP f8k072717ex5i_immucellcorp.htm EX-5.1 10667
3 SECURITIES PURCHASE AGREEMENT, DATED JULY 27, 2017, BY AND AMONG IMMUCELL f8k072717ex10i_immucellcorp.htm EX-10.1 173565
4 PRESS RELEASE OF THE COMPANY, DATED JULY 27, 2017 f8k072717ex99i_immucellcorp.htm EX-99.1 17162
5 GRAPHIC ex5i_001.jpg GRAPHIC 13604
6 GRAPHIC ex5i_002.jpg GRAPHIC 10325
  Complete submission text file 0001213900-17-007984.txt   258430
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-12934 | Film No.: 17987092
SIC: 2835 In Vitro & In Vivo Diagnostic Substances